Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2021 Nov 4:149:e237.
doi: 10.1017/S0950268821002430.

SARS-CoV-2 variants and effectiveness of vaccines: a review of current evidence

Elizabeth-Barbara Tatsi  1 , Filippos Filippatos  1 , Athanasios Michos  1
Affiliations
Review

SARS-CoV-2 variants and effectiveness of vaccines: a review of current evidence

Elizabeth-Barbara Tatsi et al. Epidemiol Infect. .

Abstract

The SARS-CoV-2 virus is rapidly evolving via mutagenesis, lengthening the pandemic, and threatening the public health. Until August 2021, 12 variants of SARS-CoV-2 named as variants of concern (VOC; Alpha to Delta) or variants of interest (VOI; Epsilon to Mu), with significant impact on transmissibility, morbidity, possible reinfection and mortality, have been identified. The VOC Delta (B.1.617.2) of Indian origin is now the dominant and the most contagious variant worldwide as it provokes a strong binding to the human ACE2 receptor, increases transmissibility and manifests considerable immune escape strategies after natural infection or vaccination. Although the development and administration of SARS-CoV-2 vaccines, based on different technologies (mRNA, adenovirus carrier, recombinant protein, etc.), are very promising for the control of the pandemic, their effectiveness and neutralizing activity against VOCs varies significantly. In this review, we describe the most significant circulating variants of SARS-CoV-2, and the known effectiveness of currently available vaccines against them.

Keywords: Severe acute respiratory syndrome coronavirus 2; spike mutations; vaccines; variants of concern.

PubMed Disclaimer

References

    1. Gorbalenya AE et al. (2020) The species severe acute respiratory syndrome-related coronavirus: classifying 2019-nCoV and naming it SARS-CoV-2. Nature Microbiology 5, 536–544. - PMC - PubMed
    1. Li W et al. (2005) Bats are natural reservoirs of SARS-like coronaviruses. Science (80-) 310, 676–679. - PubMed
    1. Rabaan AA et al. (2020) SARS-CoV-2, SARS-CoV, and MERS-CoV: a comparative overview. Le Infezioni in Medicina Med 28, 174–184. - PubMed
    1. Zhu N et al. (2020) A novel coronavirus from patients with pneumonia in China, 2019. The New England Journal of Medicine 382, 727–733. - PMC - PubMed
    1. Lu R et al. (2020) Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding. The Lancet 395, 565–574. - PMC - PubMed